Article Data

  • Views 442
  • Dowloads 118

Original Research

Open Access

Ten-year survival in patients with endometrial adenoacanthoma and endometrial adenocarcinoma with malignant squamous cell differentiation

  • U. Indraccolo1,*,
  • R. Martinello1
  • G. Scutiero1
  • G. Bernardi1,2
  • C. Borghi1
  • O. Brasile1,2
  • P. Greco1,2

1Department of Reproduction and Growth, Obstetric and Gynaecology Unit, Azienda Ospedaliero-Universitaria Arcispedale Sant'Anna of Cona, Italy

2Department of Morphology, Surgery and Experimental Medicine, Section of Obstetric and Gynaecology, University of Ferrara, Ferrara 06024, Italy

DOI: 10.31083/j.ejgo.2020.03.5376 Vol.41,Issue 3,June 2020 pp.361-363

Submitted: 30 September 2019 Accepted: 24 October 2019

Published: 15 June 2020

*Corresponding Author(s): U. Indraccolo E-mail:


Objectives: It is acknowledged that squamous differentiation in the endometrial adenocarcinoma does not affect the outcome of type I cancer. However, it has been recently reported that the so-called shadow cell differentiation is likely present in endometrial adenoacanthomas. As the shadow cells differentiation suggests a caspase-independent cell death, based on the previous reports it can be hypothesized that the endometrial adenoacanthoma would have a better prognosis than the endometrial adenocarcinoma with squamous differentiation. Methods: From a database of 829 endometrial cancer, 34 endometrial adenoacanthomas and 18 endometrial adenocarcinomas with malignant squamous differentiation were assessed. The Kaplan-Meier curves were generated and compared for endometrial adenoacanthomas and endometrial adenocarcinomas with malignant squamous differentiation. Results: the 10-year survival in patients with adenocarcinoma with malignant squamous differentiation is significantly lower than the survival in patients with adenoacanthoma. Advanced stage (2009 FIGO II or over) was more likely found in adenocarcinoma with malignant squamous differentiation at the surgery time. Matching groups for the FIGO stage, there were no difference in overall survival. Conclusion: patients with endometrial adenoacanthoma have a better prognosis than patients with endometrial adenocarcinoma with malignant squamous differentiation probably because of the earlier stage diagnosis.


Endometrial adenocarcinoma; Adenoacanthoma; Squamous cell differentiation

Cite and Share

U. Indraccolo,R. Martinello,G. Scutiero,G. Bernardi,C. Borghi,O. Brasile, P. Greco. Ten-year survival in patients with endometrial adenoacanthoma and endometrial adenocarcinoma with malignant squamous cell differentiation. European Journal of Gynaecological Oncology. 2020. 41(3);361-363.


[1] De Palo G., Kenda R., Andreola S., Luciani L., Musumeci R., Rilke F.: “Endomatrial carcinoma: stage I. A retrospective analysis of 262 patients”. Obstet. Gynecol., 1982, 60, 225.

[2] Demopoulos R.I., Dubin N., Noumoff J., Blaustein A., Sommers G. M.: “Prognostic significance of squamous differentiation in stage I endometrial adenocarcinoma”. Obstet. Gynecol., 1986, 68, 245.

[3] Zainio R.J., Kurman R.J.: “Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma”. Semin. Diagn. Pathol., 1988, 5, 154.

[4] Abeler V.M., Kiørstad K.E., Berle E.: “Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population”. Int. J. Gynecol. Cancer., 1992, 2, 9.

[5] Behbakht K., Yordan E.L., Casey C., DeGeest K., Massad L.S., Kirschner C.V., et al.: “Prognostic indicators of survival in ad-vanced endometrial cancer”. Gynecol. Oncol., 1994, 55 (3 Pt 1), 363.

[6] Zainio R.J., Kurman R., Herbold D., Gliedman J., Bundy B.N., Voet R., et al.: “The significance of squamous differentiation in endome-trial carcinoma. Data from a Gynecologic Oncology Group study”. Cancer., 1991, 68, 2293.

[7] SGO Clinical Practice Endometrial Cancer Working Group., Burke W. M., Orr J., Leitao M., Salom E., Gehrig P., Olawaiye A.B., et al.; Society of Gynecologic Oncology Clinical Practice Committee.: “Endometrial cancer: a review and current management strategies: part I”. Gynecol. Oncol., 2014, 134, 385.

[8] Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J., et al.; ESMO-ESGO-ESTRO Endometrial Con-sensus Conference Working Group.: “ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up”. Int. J. Gynecol. Cancer., 2016, 26, 2.

[9] Pekin T., Yildizhan B., Eren F., Pekin O., Yildizhan R.: “Adenocar-cinoma, adenoacanthoma, and mixed adenosquamous carcinoma of the endometrium”. Eur. J. Gynaecol. Oncol., 2001, 22, 151.

[10] Nakamura T.: “Shadow cell differentiation from squamoid morule in endometrial adenoacanthoma”. Int. J. Clin. Exp. Pathol., 2015, 8, 13120.

[11] Nakamura T.: “Shadow cell differentiation: a comparative analysis of modes of cell death with apoptosis and epidermal/trichilemmal keratinization”. Dermatopathology. (Basel)., 2018, 5, 86.

[12] Greco P., Martinello R., Indraccolo U., Borghi C., Bonaccorsi G., Scutiero G.: “Outcome of endometrial cancer after lymphadenec-tomy: a single center retrospective analysis with long-lasting follow-up”. Minerva. Ginecol., 2017, 69, 405.

[13] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time